Seeking advice from dut non-responders who used RU Update 8/12/2025
The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity What are some promising/revolutionizing treatments that are in the pipeline/currently available?
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
community How likely do you think it is for PP405 to come out?
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
community Don’t Get Too Hyped About PP405. We've Seen This Movie Before.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
community Switch from fin to dut and its worse
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
community Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.
research Androgens and Parkinson’s disease: the role in humans and in experiment
This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.
research Системная терапия больных андрогенетической алопецией
Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.